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Background:  Staphylococcus  aureus  is a pathogen  which  causes  life-threatening  infection,  the  incidence
of  which  rises  during  adult  life.  This,  together  with  the  emergence  of drug-resistant  strains  and  the
expansion  of more  susceptible  elderly  populations,  represents  the  rationale  for the  ongoing  development
of  S.  aureus  vaccines  targeting  adult  populations.  Humoral  responses  to S. aureus  naturally  develop  early
in life,  inﬂuence  susceptibility  to infection,  and  potentially  inﬂuence  the  effect  of  vaccination.  Despite  this,
the  nature  of  pre-existing  anti-S.  aureus  antibodies  in  healthy  adult  populations  is not  fully  characterised.
Methods:  Immunoglobulin  levels  against  S. aureus  surface  antigens  were  measured  by  a ﬁlter  membrane
enzyme-linked  immunosorbent  assay  using ﬁxed  SpA  S.  aureus  as  an  antigen  in  serum  samples  obtained
from  three  clinical  cohorts  comprising  133  healthy  adult  volunteers  from  19  to 65 years  of age. Functional
capacity  of  antibody  was  also  assessed,  using  antibody-mediated  attachment  of  FITC-stained  S. aureus  to
differentiated  HL-60  cells.
Results:  Wide  variation  in  the  concentrations  of  immunoglobulins  recognising  S. aureus  surface  antigens
was  observed  among  individuals  in  all three  cohorts.  There  was  a decline  of anti-S.  aureus  IgG1  with
age,  and  a similar  trend  was  observed  in  IgM, but not  in  IgA  or other  IgG  sub-classes.  Antibody  mediated
bacterial  attachment  to cells  was  associated  with  IgG1  and  IgG3 concentrations  in  serum.  The  presence  of
SpA on the  bacterial  cell  surface  reduced  antibody-mediated  binding  of bacteria  to phagocytes  in  serum
with low,  but  not  high,  levels  of naturally  occurring  anti-S.  aureus  IgG3  antibodies.
Conclusions:  Naturally  acquired  immunoglobulin  responses  to S. aureus  are  heterogeneous  in populations
and  their  concentrations  alter  during  adulthood.  Elevated  IgG1  or  IgG3  titres  against  S.  aureus  enhance  S.
aureus recognition  by phagocytosis  and  may  be  correlates  of  natural  protection  and/or  vaccine  efﬁcacy
in  adult  populations.
© 2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. IntroductionStaphylococcus aureus is a human pathogen primarily found
n the anterior nares [1], and asymptomatic persistent carriage
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of the bacterium occurs in ∼30% of the general population [2].
S. aureus infections can range from mild skin conditions to
invasive bacteraemia and pneumonia [3]. Persistent exposure
to S. aureus,  as occurs in S. aureus carriage, appears to confer
some limited protection from some forms of S. aureus disease
[4], while epidemiological data showing a gradual increase of
the invasive disease incidence rate with increasing age, most
marked from the age of about 40 years upwards [5,6], might
be compatible with a slow decline of natural protection with
ageing.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Table 1
Demographic data of three clinical cohorts.
Cohort A B C
Number of participants 36 26 71
Average age
(years ± S.E.)
31.9 ± 1.34 35.7 ± 1.45 38.1 ± 1.45
Number of volunteers in each age group
19–30 15 6 28
31–40 17 13 16
41–50 3 6 10
51–60 1 1 14
61–70 0 0 3
Male (rate) 36 (1) 10 (0.38) 25 (0.35)
S.  aureus nasal carriage 15 (0.30) 8 (0.31) NDJ. Whitehouse et al. / Va
S. aureus is listed by WHO  as a growing healthcare and eco-
omic concern due to development of antibiotic resistance [7,8].
n the absence of new antibiotic discovery, vaccination is consid-
red an alternative approach to control S. aureus infection. Humoral
mmunity mediates opsonisation of S. aureus and induces clearance
y neutrophils [9,10]. Successful passive immunisation against
he surface protein A (SpA) immune subversion antigen has been
emonstrated in a murine challenge model [11]. Although S. aureus
accines have, to date, failed in phase III clinical trials, new can-
idates inducing humoral immunity against cell surface proteins
re in development [12–14]. Such vaccines will be deployed into
 previously exposed human population, since antibody responses
gainst S. aureus antigens start to rise in the ﬁrst years of life and
emain detectable through adulthood [15–17].
Immunoglobulin G (IgG) is the predominant isotype found in
erum, comprising ∼15% of plasma protein, and is further divided
nto 4 sub-classes (IgG1, IgG2, IgG3, and IgG4), classiﬁed in terms
f their abundance and of functional differences [18,19]. While the
ab region of the antibody binds to speciﬁc antigen, the constant
c region interacts with the host immune system, e.g. Fc recep-
ors (FcRs), to initiate downstream effects such as phagocytosis
nd antibody dependent cellular cytotoxicity, complement acti-
ation, and the release of reactive oxygen species [20–22]. Most
linical isolates of S. aureus express and secrete SpA [23], which
equesters human IgG sub-classes 1, 2 and 4 through high-afﬁnity
inding to the Fc region [24], thus interfering with antibody inter-
ction with host cells and complement in in vivo and in vitro. As a
esult, S. aureus suppresses antibody-mediated immunity, impedes
hagocytosis by human neutrophils, and interacts with B cell recep-
ors inducing activation and subsequent cell death [25,26]. Thus,
n effective antibody response against S. aureus has to overcome
he immunomodulatory inﬂuence of SpA. Interestingly, its afﬁnity
or IgG3 is much lower and is allotype-speciﬁc [27], yet the levels
f each IgG sub-class detecting S. aureus in individuals have not
een investigated as being of relevance to SpA-mediated immune
vasion.
Since naturally-acquired immunity against S. aureus is poorly
nderstood, we investigated the variation of a range of isotypes
f naturally-acquired antibodies against S. aureus within three
ealthy human populations, as well as their impact on SpA function.
e discuss natural variation in titre and isotypes in the context of
oth vaccine response and natural protection from clinical infection
n man.
. Materials and methods
.1. Experimental design and sampling
Antibody responses against S. aureus surface antigens were
creened using serum collected from three separate cohorts of
ealthy adults, aged between 19 and 65 years old (Table 1).
Cohort A: Royal Navy submariners (n = 50) were involved in Sur-
eon General’s Armed Forces Feeding Project, which included a
tudy assessing the impact of S. aureus carriage on skin health
manuscript in progression), and provided written consent. A nasal
wab and serum sample were taken between 24 and 72 h after
onsent was obtained, and before deployment. The medical ofﬁcer
n-board obtained a follow-up nasal swab from all submariners
fter a 40-day deployment. Serum samples were separated within
 h of sampling and were stored initially at −20 ◦C, then at −80 ◦C.
4 out of 50 individuals were excluded from antibody analysis
ecause of missing baseline questionnaire (n = 6), missing age data
n = 1), missing blood sampling (n = 5), missing post nasal swab
n = 4), and/or because of a technical problem with serum stor-
ge conditions (n = 3). 36 volunteer samples with complete clinical(rate)
ND, not determined.
data were analysed for serum antibody responses against S. aureus
surface antigens.
Cohort B: Healthy adult volunteers, declaring themselves to
be of Northern European ancestry, were recruited in Oxford-
shire, UK (n = 26), as part of a S. aureus nasal carriage study
(manuscript in progression). Exclusion criteria were: pregnancy,
taking immunomodulatory drugs, diagnosis of cancer, connective
tissue disease, blood borne viruses, or organ transplantation. Writ-
ten consent was obtained, a questionnaire administered, and a
nasal swab and blood taken on the day of recruitment. Serum sam-
ples were stored at −80 ◦C. A second nasal swab was  obtained
between 1 and 2 months later from all subjects.
Cohort C: Healthy adult volunteers were recruited in Oxford-
shire, UK (n = 400), for screening of healthy serum samples in
immunoassays for vaccine development. There were no exclusion
criteria for enrolment. Serum samples were stored at −80 ◦C and
71 samples were randomly selected for antibody analysis.
2.2. Ethical approval
The study performed on Royal Navy servicemen (cohort A) was
approved by the UK Ministry of Defence Research Ethics Committee
(MODREC), Ref. 0903/228. The two human volunteer studies per-
formed in Oxford (cohorts B and C) were approved by the National
Research Ethics Service (NRES) Committee South Central (reference
number 11/SC/0307), and NRES Committee South West (reference
number 10/H0102/23), respectively.
2.3. Determination of nasal carriage
In both cohorts A and B, individuals with two positive swabs
were considered persistent carriers [28]. Nasal samples were
processed as described [28].
2.4. Enzyme linked immunosorbent assay (ELISA) for
immunoglobulin isotyping
The assay was  performed as described previously [29]. Brieﬂy,
2 × 107 CFU/well paraformaldehyde (PFA)-ﬁxed S. aureus spa::TcR
isogenic DU5873 mutant [30] (obtained from Prof. Tim Foster,
Trinity College, Dublin) (SpA Newman strain) were immo-
bilised on ﬁlter plates (Merck Millipore, MAGVS2210). Plates
were blocked and incubated overnight with different serum con-
centrations. Plates were washed using MultiScreenHTS Vacuum
Manifold (Merck Millipore) and incubated with various anti-human
secondary antibodies [IgG1-HRP (Life Tech., MH1715); IgG2-ALP
(Abcam, ab99783); IgG3-ALP (Abcam, ab99828); IgG4-ALP (Abcam,
ab99822); IgG-ALP (Sigma, A3187); IgA-ALP (Sigma, A9669); IgM-
ALP (Sigma, A3275)]. After further washing, the relevant substrate
was added [tetramethylbenzidine or p-nitrophenyl phosphate
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Sigma)]. The reaction was stopped by addition of 2 N H2SO4 or 2 N
aOH (Scientiﬁc Laboratory Supplies), and 100 L of the reaction
as transferred into clean 96 well plates (NUNC). Absorbance was
ead at 450 nm or 405 nm,  depending on substrate (CLARIOstar®,
MG  Labtech). A 4 Parameter Logistic (4PL) nonlinear regression
odel was used for all ELISA assays for the interpolation from a
eference serum. The concentration of each immunoglobulin iso-
ype in this reference serum was assigned a concentration of 5 log10
LISA units per ml  (log10 unit/mL).
Speciﬁcity of binding for IgG and IgG1 sub-class was assessed
y incubation of the target cells with IgG1 from human myeloma
lasma (Sigma–Aldrich, I5154) at between 0 and 102 g/mL,
nstead of serum. These experiments indicated that the DU5873
utant did not bind detectably to the irrelevant IgG preparation.
.5. Luciferase immunoprecipitation systems (LIPS) assay
The LIPS assay [31] was used to determine the IgG response
gainst SpAKKAA, a mutated SpA D domain lacking Fc binding activ-
ty [32]. Brieﬂy, plasmid constructs of the SpAKKAA sequence fused
ith renilla luciferase were transfected into HEK293 cells and cell
ysates stored at −80 ◦C for further use. Serially diluted human
erum was incubated with cell lysate, then added to Protein G
ltraLink Resin (ThermoScientiﬁc) in ﬁlter plates (Merck Millipore,
SGVN2B50). After overnight incubation and subsequent wash-
ng, assay substrate was added (Renilla luciferase assay system,
romega UK Ltd) and chemoluminescence measured in a Lumi-
ometer (CLARIOstar®, BMG  Labtech). A 4PL nonlinear regression
odel was used for the interpolation from a reference serum. The
oncentration of this reference serum was assigned a concentra-
ion of 4 log10 luciferase activity units per ml  (log10 luciferase
nit/mL).
.6. Antibody-mediated interaction of differentiated HL-60 cells
ith S. aureus
29 serum samples from cohorts A and B were randomly selected,
eat inactivated at 56 ◦C for 30 min, then stored at −80 ◦C until used.
he acute myeloid leukaemia cell line HL-60 cells (obtained from
rof. Andrew Pollard) were cultured in RPMI 1640 medium contain-
ng 2 mM l-glutamine supplemented with 10% foetal bovine serum
all from Sigma) with 100 mM N,N-dimethylformamide (Fisher Sci-
ntiﬁc) for 3 days for differentiation to FcR  expressing phagocytes
33]. S. aureus (wild-type and SpA Newman strains) were incu-
ated in 10 ml  tryptic soya broth (Oxoid) overnight and used to
et fresh cultures for 1.5 h growth. Bacteria were washed and
tained with FITC (Sigma), then incubated with heat-inactivated
erum for 10 min  at 37 ◦C with shaking at 130 rpm. Antibody-coated
acteria were washed and resuspended in medium. Differentiated
L-60 cells in medium were added to the wells containing bacte-
ia (2 × 105 cells to 1 × 106 CFU per well) and incubated at 37 ◦C for
5 min  with shaking at 130 rpm. Samples were placed on ice imme-
iately after incubation and cells were stained with Aqua live/dead
tain (Invitrogen) then ﬁxed with 4% PFA. Data was acquired with
 CyAn7 cytometer and analysed with Summit analysis software
4.3.01 (Dako Colorado, Inc.). Antibody-mediated binding of bacte-
ia to phagocytes was measured as a percentage of cell-associated
uorescence (FITC+ HL-60 cells) (Fig. 3A–F), where the background
ignal was 2.76 ± 0.60% without pre-incubation of bacteria with
erum (Fig. 3E). Inhibitory effect of SpA on antibody-mediated
inding of bacteria to phagocytes per sample was  calculated
y: (% HL-60 cells with FITC+ SpA) − (% HL-60 cells with FITC+
ild-type). 34 (2016) 1792–1799
2.7. Statistical analysis
Statistical analysis was performed using GraphPad Prism ver-
sion 6.03, IBM SPSS Statistics version 22, and R 3.1.1 for Windows.
Analysis was performed on log10 transformed data, using linear
regression and generalised linear modelling with Wald-chi square
test, and Spearman rank correlation tests. Linear modelling of inter-
action assay was performed using the glm function in R.
3. Results
3.1. IgG1 levels against S. aureus surface antigens show decline
with age
Serum IgM, IgG and IgA levels were measured against SpA
S. aureus Newman strain in cohort A. There was  a wide varia-
tion in baseline levels of these immunoglobulins recognising the S.
aureus surface (Fig. 1), with about 10-fold variation between indi-
viduals. There were trends towards decline of IgM (p = 0.052) and
IgG binding (p = 0.08) to S. aureus surface antigens with increasing
age (Fig. 1A and B), while anti-S. aureus IgA levels were more stable
(Fig. 1C). Of all the IgG sub-classes, only anti-S. aureus IgG1 levels
showed a negative correlation with age (Fig. 1E–H). Since the anti-
gen lacked SpA, anti-S. aureus IgG response against a recombinant
SpA domain with KKAA mutations [32] which abrogate Fc binding,
was also measured. The anti-SpAKKAA IgG response was not signiﬁ-
cantly associated with age (Fig. 1D), so it is possible that age-speciﬁc
decline in IgG titres is restricted to only some cell surface antigens.
To determine whether the pattern seen in the submariner
cohort, all of which was male, was  representative of the general
population, serum IgG1 levels against SpA S. aureus surface anti-
gens were analysed in healthy adults in Oxfordshire (cohort B and
C). The inverse relationship of anti-S. aureus IgG1 with age was  con-
ﬁrmed in these populations (Fig. 2A), and this was evident in both
genders (Fig. 2B). S. aureus nasal carriage status was  determined
in cohort A and B (Table 1), and an age-associated anti-S. aureus
IgG1 decline was observed in both S. aureus nasal carriers and non-
carriers (Fig. 2C). Notably, and similarly to the result observed with
cohort A, the levels of anti-S. aureus IgG3 did not decline signiﬁ-
cantly with age in either cohorts B or C (Fig. 2D). Of note, most of
the subjects studied (120/136) were aged between 19 and 50, and
the age associated decline observed was driven by these individuals
(Spearman’s rho = −0.2874 p = 0.002, for those age 50 or under).
3.2. IgG levels against SpA S. aureus surface antigens correlates
with functional capability
Uptake of antibody-opsonized pathogens by phagocytes,
through Fc-mediated receptor binding [34], is an important func-
tion of pathogen speciﬁc immunity. To assess this, we adapted the
opsonophagocytic assay using the HL-60 cell line [33], which can be
differentiated into Fc receptor positive neutrophil-like cells in vitro,
providing a consistent supply of phagocytic cells for assessing
Fc-receptor mediated pathogen binding, and ﬂuorescent labelled
bacteria to measure the rate of bacteria-bound cells by ﬂow cytom-
etry [35,36]. In vitro culture of opsonised FITC+ S. aureus SpA with
HL-60 cells showed a positive correlation between serum anti-S.
aureus IgG titres and percentages of cell-associated ﬂuorescence,
suggesting that anti-S. aureus IgG levels correlate with functional
capacity to mediate phagocyte–antigen interaction (Fig. 3G).
If this cell-associated ﬂuorescence requires Fc binding of anti-
body to Fc receptors, the interaction should be reduced by SpA,
which mediates non-speciﬁc immunoglobulin Fc binding [24].
The same assay was  performed using wild-type S. aureus;  cell-
associated ﬂuorescence was reduced in presence of SpA for most
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owever, the inhibitory effect of SpA, measured as the difference
etween the cell-associated ﬂuorescence of SpA and wild-type
. aureus,  diminished as anti-S. aureus IgG titres increased (Fig. 3I).
hus, endogenous levels of IgG against S. aureus surface antigens
orrelates with functional activity, and the immunoevasive effect
f SpA is greater at lower concentrations of anti-S. aureus IgG.of IgM (A), IgG (B) and IgA (C) binding to S. aureus SpA surface antigens, luciferase
asses binding to S. aureus SpA surface antigens (E–H): all plotted against age.
3.3. High serum IgG3 titre against S. aureus diminishes the
immunoevasive effect of SpA
Afﬁnities of SpA to each IgG sub-class are different, thus nega-
tive association of anti-S. aureus IgG titre and inhibitory effect of
SpA may  be differently inﬂuenced by the concentration of each IgG
sub-class. Correlations between percentages of cell-associated ﬂu-
orescence with wild-type S. aureus and levels of anti-S. aureus IgG
1796 J. Whitehouse et al. / Vaccine 34 (2016) 1792–1799
Fig. 2. Association of IgG1 and IgG3 levels against S. aureus to age, gender and S. aureus carriage status. (A) Correlation plots of IgG1 responses to S. aureus SpA surface
a ison o
a se to 
s
o
t
o
I
w
c
c
I
c
o
s
I
w
n
t
T
e
a
r
T
C
v
bntigens vs. age in cohort B (closed squares) and cohort C (open triangles). Compar
ureus  nasal carriage status (C: cohort A and B). (D) Correlation plots of IgG3 respon
ub-classes showed a strong positive relationship between levels
f anti-S. aureus IgG3 and cell-associated ﬂuorescence of wild-
ype S. aureus,  while there were no associations with IgG1, IgG2
r IgG4 using univariate analysis (Fig. 4, top panels). Anti-S. aureus
gG sub-class titres within the general population displayed only
eak correlations with each other (maximum r = 0.27 between sub-
lasses, Table 2), which allowed multivariate analysis, modelling
ell-associated ﬂuorescence of wild-type S. aureus as a function of
gG1, 2, 3 and 4 concentrations. A multivariate model supported a
ontribution of IgG3 to cellular-bacterial interaction, independent
f other sub-classes (p = 2.2 × 10−6 in multivariate model). It also
uggested that an independent role may  be played by anti-S. aureus
gG1 (p = 0.007 in multivariate model).
Levels of anti-S. aureus IgG sub-classes were then compared
ith the impact of SpA on cell-associated ﬂuorescence. There was a
egative correlation between effect of SpA and anti-S. aureus IgG3
itres, but not with titres of other IgG isotypes (Fig. 4, bottom panel).
hus antibody-mediated binding of cells and S. aureus was inﬂu-
nced by concentrations of anti-S. aureus IgG3 and IgG1 in serum,
nd that increased concentrations of IgG3 within the physiological
ange can overcome the effect of SpA.
able 2
orrelation matrix of IgG sub-classes. Pearson correlation coefﬁcients for n = 29 indi-
iduals of cohort A and B, the sera of which was  used to assess antibody-mediated
inding of HL-60 cells and FITC+ wild-type S. aureus.
IgG1 IgG2 IgG3 IgG4
IgG1 1.00 −0.20 −0.09 −0.25
IgG2 −0.20 1.00 0.24 0.27
IgG3 −0.09 0.24 1.00 −0.23
IgG4 −0.25 0.27 −0.23 1.00f age associated anti-S. aureus IgG1 decline between gender (B: cohort A–C) and S.
S. aureus SpA surface antigens vs. age (cohort B and C).
4. Discussion
This paper describes an age-associated decline of naturally
induced IgG1 antibodies against S. aureus surface antigens, and het-
erogeneity of concentrations of immunoglobulin isotypes against
S. aureus in healthy adults between 19 and 65 years old. This age-
dependent decline in IgG1 titre against S. aureus surface antigens
is congruent with reports of a decline in IgG responses to ClfB, a
S. aureus surface antigen, with increasing age [17]. While natu-
rally acquired human IgG1 and IgG3 titres against S. aureus were
associated with antibody-mediated S. aureus attachment to phago-
cytes, attachment was attenuated by SpA in sera with low, but
not high, IgG3 levels. Since antibody-dependent uptake and killing
of S. aureus by neutrophils is the primary mechanism of bacterial
clearance by the host immune system [10,37], the naturally occur-
ring variation in antibody responses, attenuated by SpA to different
degrees between individuals, may  inﬂuence both natural protec-
tion from infection and post-vaccination immune response in man.
Since IgM and IgG1 are the major immunoglobulin isotypes present
in serum, we suggest that the age-associated decline observed in
this study is likely to contribute to an increased risk of invasive S.
aureus disease in the middle-aged to elderly [38]. The implication
is that boosting of immune responses in the middle-aged popula-
tion, before the waning of adaptive immunity to sub-optimal levels
[39,40] and prior to the period of highest risk, as occurs with immu-
nity to Varicella zoster virus [41], may  improve later-life immune
responses. Of note, the study cohorts were mainly composed of
individuals from 19 to 50 years old, with none over 65 years old.
The effect described was observed if one restricts to individuals
under 50 years of age. Therefore, one could speculate that a fur-
ther decline of IgG1, and possibly IgM, against S. aureus would be
observed in the population above 65 years of age. This, together
with an exploration of whether such effects also occur against
J. Whitehouse et al. / Vaccine 34 (2016) 1792–1799 1797
Fig. 3. Detection of antibody-mediated binding of FITC+ S. aureus to differentiated HL-60 cells. (A–F) FACS analysis gating strategies; cells were gated for singlets (A) then
AQUA  negative live cells (B) before analysing percentage of FITC+ cells. Live cells were plotted on FCS vs SSC (C). Example plots of differentiated HL-60 cells alone (D),
differentiated HL-60 cells with FITC+ S. aureus without serum pre-treatment (E), and differentiated HL-60 cells with FITC+ S. aureus pre-treated with heat-inactivated serum
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ll  plotted against ELISA IgG response to SpA S. aureus surface antigens.
ther bacterial pathogens, including Gram negative pathogens, is
n important area for further investigation. In this study, although
odelling indicates that IgG1 (which declines during adult life)
ontributes to opsonophagocytosis, it was notable that the anti-
. aureus IgG3 response was found to be independent to the effect
f ageing, and the concentrations of this sub-class correlated to
he interaction of phagocytes with wild-type S. aureus,  presumably
ue to its low afﬁnity for Fc-mediated sequestration by SpA. IgG3
ependent protection may  also operate by other means, such as
peciﬁc enhancement of antibody dependent cellular cytotoxicity,
s suggested by analysis of the ALVAC-HIV (‘Thai trial’) in which-60 cells attached to FITC+ SpA S. aureus, (H) percentage of differentiated HL-60
 HL-60 cells associated with FITC+ SpA S. aureus minus FITC+ wild-type S. aureus;
IgG3 levels against HIV were associated with protection [42]. Stabil-
ity of anti-S. aureus IgG3 responses across the age groups indicates
that naturally acquired levels of anti-S. aureus IgG3 alone cannot
maintain the level of protection required. Considering its low abun-
dance and short half-life in serum [19], induction of IgG3 responses
along with the maintenance of IgG1 levels may  be possible correlate
of vaccine efﬁcacy and natural protection in the population above
middle age.
One limitation concerns the use of serum as a source of antibod-
ies during our in vitro studies. Physiologically the site of interaction
of antibody with the cell surface of S. aureus is usually mucosal, and
1798 J. Whitehouse et al. / Vaccine 34 (2016) 1792–1799
Fig. 4. Association of % FITC+ HL-60 cells and anti-S. aureus IgG sub-class levels. Percentage of differentiated HL-60 cells associated with FITC+ wild-type S. aureus (top panels),
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unctional antibody–bacterium interactions at this site have been
tudied for Streptococcus pyogenes, another IgG binding bacterium
43]. Antibody concentrations in mucosal ﬂuids, such as saliva, are
uch lower than in serum, and the impact of SpA on the function
f the sub-classes present in the saliva of human populations may
e much more pronounced than that evident in our studies using
erum, as described for S. pyogenes [43]. This area could be studied
urther.
Independent of the mechanisms behind IgG sub-class action
gainst S. aureus,  the data presented suggest emphasis needs
o be placed on the quality of the immune response generated
oth by natural exposure and vaccination programmes. In partic-
lar, we suggest that the age-associated decline of anti-S. aureus
mmunoglobulin isotypes, particularly IgG1, perhaps combined
ith the documented decline in neutrophil function, including
hagocytosis and respiratory burst, which occurs with age [44],
ay  be contribute to rising S. aureus susceptibility in the vul-
erable patient group. Better understanding of naturally-acquired
mmunity, correlated with epidemiological data may assist logi-
al vaccine design when attempting to protect a population with
eterogeneous pre-existing immunity against S. aureus infection.
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